156 related articles for article (PubMed ID: 17011081)
1. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].
Haddad L; Perrinet M; Parent D; Leroy-Cotteau A; Toguyeni E; Condette-Wojtasik G; Hachulla E
Rev Med Interne; 2006 Dec; 27(12):924-6. PubMed ID: 17011081
[TBL] [Abstract][Full Text] [Related]
2. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
3. [Subcutaneous immunoglobulin and support program: what level of interest of patients?].
Bourdin A; Berger J; Früh A; Spertini F; Bugnon O
Rev Med Suisse; 2015 Apr; 11(469):831-5. PubMed ID: 26040165
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
Dams ET; van der Meer JW
Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254
[No Abstract] [Full Text] [Related]
6. Managing cost of care and healthcare utilization in patients using immunoglobulin agents.
Vaughan LJ
Am J Manag Care; 2019 Jun; 25(6 Suppl):S105-S111. PubMed ID: 31318516
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.
Lingman-Framme J; Fasth A
Drugs; 2013 Aug; 73(12):1307-19. PubMed ID: 23861187
[TBL] [Abstract][Full Text] [Related]
8. [IgIV at home:experience of a center--economic aspects].
Hachulla E
Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832
[TBL] [Abstract][Full Text] [Related]
9. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
[TBL] [Abstract][Full Text] [Related]
11. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance.
Högy B; Keinecke HO; Borte M
Eur J Health Econ; 2005 Mar; 6(1):24-9. PubMed ID: 15480920
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
Gardulf A; Andersen V; Björkander J; Ericson D; Frøland SS; Gustafson R; Hammarström L; Jacobsen MB; Jonsson E; Möller G
Lancet; 1995 Feb; 345(8946):365-9. PubMed ID: 7845120
[TBL] [Abstract][Full Text] [Related]
16. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
Fu LW; Song C; Isaranuwatchai W; Betschel S
Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
18. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States.
Huang F; Feuille E; Cunningham-Rundles C
J Clin Immunol; 2013 Jan; 33(1):49-54. PubMed ID: 22961047
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin replacement in primary immunodeficiencies.
Berger M
Clin Immunol; 2004 Jul; 112(1):1-7. PubMed ID: 15207776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
